Long Non-coding RNA RMRP in the Pathogenesis of Human Disorders

Bashdar Mahmud Hussen1, Tahereh Azimi2, Hazha Jamal Hidayat3, Mohammad Taheri4* and Soudeh Ghafouri-Fard2*

1 Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Erbil, Iraq, 2 Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 3 Department of Biology, College of Education, Salahaddin University-Erbil, Erbil, Iraq, 4 Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

RNA component of mitochondrial RNA processing endoribonuclease (RMRP) is a non-coding transcript firstly acknowledged for its association with the cartilage-hair hypoplasia (CHH) syndrome, a rare autosomal recessive condition. This transcript has been spotted in both nucleus and mitochondria. In addition to its role in the pathogenesis of CHH, RMRP participates in the pathogenesis of cancers. Independent studies in bladder cancer, colon cancer, hepatocellular carcinoma, lung cancer, breast carcinoma and multiple myeloma have confirmed the oncogenic effects of RMRP. Mechanistically, RMRP serves as a sponge for some miRNAs such as miR-206, miR-613, and miR-217. In addition to these miRNAs, expressions of tens of miRNAs have been altered following RMRP silencing, implying the vast extent of RMRP/miRNA network. In the present narrative review, we explain the role of RMRP in the development of cancers and some other non-malignant disorders.

Keywords: long non-coding RNA RMRP, cancer, expression, biomarkers, cell lines

INTRODUCTION

Although protein-coding genes comprise a minor portion of the mammalian genome, it has been revealed that the vast majority of these genomes is transcribed at some level (Carninci et al., 2005; Birney et al., 2007). It has also been speculated that considerable portion of these transcripts are likely functional (Mattick et al., 2010). Notably, the ENCODE consortium has described assignment of “biochemical functions” to approximately 80% of the genome (Consortium, 2012). This group of non-coding RNAs (ncRNAs) includes several members ranging from the lately described abundant ribosomal RNAs (rRNAs) (Stark et al., 1978), small nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNAs) to those with recently appreciated regulatory RNAs, namely microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) (Palazzo and Lee, 2015). miRNAs have sizes about 22 nucleotides and regulate expression of genes mostly through binding with 3’ untranslated regions of target transcripts (Macfarlane and Murphy, 2010). LncRNAs have sizes over 200 nucleotides and are transcribed by RNA Polymerase (RNA Pol) II and RNA Pol III. They modulate numerous cellular processes including histone modification, DNA methylation, and transcription of genes through modulating chromatin configuration and DNA accessibility (Dahariya et al., 2019).
RNA component of mitochondrial RNA processing endoribonuclease (RMRP) is a transcript with wide expression in diverse tissues obtained from human and mice species (Rosenbluh et al., 2011). RMRP has a regulatory role in the processing of RNA in both mitochondrial and ribosomal compartments (Hermanns et al., 2005). RMRP transcripts have been detected in both mitochondria and nucleus (Chang and Clayton, 1987; Rosenbluh et al., 2011). This IncRNA has a remarkable role in the primary stages of mice development (Rosenbluh et al., 2011). In humans, mutations in the RMRP gene has been associated with cartilage-hair hypoplasia (CHH) syndrome, a multi-systemic disorder that is inherited via an autosomal recessive mode. Clinical characteristics of CHH are unbalanced short stature, fine and scant hair, defects in cellular immunity and susceptibility to cancer which are related to defects in expression of RMRP (Hermanns et al., 2005). Although immunodeficiency is a possible underlying mechanism of malignancy in these patients, many CHH cases with no history of immunodeficiency has developed neoplastic conditions such as lymphoma, implying a multifactorial basis for development of malignancy in CHH (Vakkilainen et al., 2019b). Epstein-Barr virus infection can explain some cases of lymphoproliferative disorders in CHH (Taskinen et al., 2013; Sathishkumar et al., 2018). Yet, not all lymphoproliferative disorders are related with this virus (Nguyen et al., 1718). In addition to defects in response to viral infections, chromosomal instability (Hauck et al., 2018) and impaired telomere function (Kostjkovits et al., 2017) might explain the increased risk of malignancy in CHH. A high throughput expression assay in CHH fibroblasts has shown abnormal expression of tens of gene. Notably, under-expressed genes have been functionally associated with cell cycle. Moreover, regulatory pathways of apoptosis, bone and cartilage development, and functions of lymphocyte, and PI3K-Akt cascade have been among other dysregulated mechanisms. CHH cells have exhibited delays in the transition from G2 stage to mitosis (Vakkilainen et al., 2019a). Experiment in Zebrafish model of CHH produced by Rmrp knock-down has verified the role of over-activation of Wnt/β-Catenin signaling in disruption of chondrogenesis and bone ossification (Sun et al., 2019). Although RMRP has been shown to bind with the mitochondrial RNA processing complex RNase MRP (Chang and Clayton, 1987), there is no obvious mitochondrial deficiencies in CHH patients. In conjunction with IiTERT, RMRP can make an RNA dependent RNA polymerase which transforms single stranded RMRP transcript into double stranded form (Maida et al., 2009). Over-expression of RMRP has been demonstrated in a wide spectrum of human malignancies (Tang et al., 2019). In the present narrative review, we explain the role of RMRP in the development of cancers and some other non-malignant disorders.

**MALIGNANT CONDITIONS**

**Cell Line Studies**

In the cholangiocarcinoma cells, up-regulation of RMRP is associated with down-regulation of miR-217, a miRNA that is sequestered by RMRP (Tang et al., 2019). RMRP silencing has resulted in up-regulation of several miRNAs such as hsa-miR-33a-3p, hsa-miR-186-5p, and hsa-miR-216a-5p, while down-regulation of hsa-miR-345-5p, hsa-miR-1275, and hsa-miR-4454 (Tang et al., 2019). RMRP silencing can suppress proliferation of cholangiocarcinoma cells, stimulate apoptosis in these cells, and block them in the G0/G1 stage (Tang et al., 2019). In lung cancer cells, RMRP silencing evidently reserved cell proliferation, migration, and invasiveness, while blocking cell cycle transition. miR-1-3p has been identified as a target of RMRP in these cells (Tang et al., 2019). Figure 1 displays the mechanism of RMRP-mediated oncogenesis in lung cancer.

In the bladder cancer cell lines, RMRP can enhance proliferation, migration potential and invasiveness of cells through modulating expression of miR-206 (Cao et al., 2019), a tumor suppressor miRNA that induces cell cycle arrest (Huang et al., 2016). Based on the presence of the β-catenin/TCF and YAP/TBX5 constituents in the upper parts of the RMRP gene, expression of RMRP might be associated with the cancer-associated pathways, Wnt/β-catenin and Hippo/YAP. Functional studies have shown that induction of Wnt signaling enhances expression of RMRP via β-catenin and YAP nuclear factors (Park and Jeong, 2015). In hepatocellular carcinoma cells, RMRP silencing has precluded cell proliferation, migration and invasive properties, while stimulating cell cycle arrest. These effects are mediated by sponging miR-613 (Zhou et al., 2019). Another study in this type of cancer has shown the role of RMRP in sequestration of miR-206 and activation of TACR1/Erk1/2 pathway (Hongfeng et al., 2020). However, Shao et al. (2020) have demonstrated down-regulation of RMRP in the hepatocellular carcinoma cells. Enforced over-expression of RMRP in these cells enhanced apoptosis rate of these cells through modulating miR-766 expression (Shao et al., 2020). RMRP silencing in gastric cancer cells suppresses cell proliferation via modulation of miR-206 and subsequent regulation of cell cycle transition through modulation of Cyclin D2 (Shao et al., 2016). In the neuroblastoma cells, the oncogenic effects of RMRP are mediated through sequestering miR-206 and enhancing expression of TACR1 (Pan et al., 2019). In the papillary thyroid carcinoma cells, expression of RMRP has been increased while expression of miR-675 has been diminished. MAPK1 has been identified as a target of miR-675 in these cells (Wang et al., 2019). A brief review of investigations that appraised RMRP expression in cancer-derived cell lines is presented in Table 1.

**Animal Studies**

*In vivo* assays have verified the cancer-promoting effects of RMRP. RMRP silencing has attenuated tumorigenesis process in xenograft model of liver cancer through modulation of miR-613 expression (Zhou et al., 2019). However, another *in vivo* study demonstrated the opposite role for RMRP in the pathogenesis of hepatocellular carcinoma through modulation of miR-766 (Shao et al., 2020). RMRP silencing has decreased the rate of growth of cholangiocarcinoma in animal models in association with the frequency of Ki-67-positive cells in these tumors (Tang et al., 2019).
RMRP has been over-expressed in lung cancer (Shao et al., 2016). This IncRNA acts as a sponge for miR-613 and miR-206. miR-206 binds with 3’UTR of NFAT5 transcription factor (Yang et al., 2020). This transcription factor increases expression of AQP5 (Guo and Jin, 2015) and the heat shock protein HSP70 which increases stability of lysosome membrane (Boya and Kroemer, 2008). As a member of HSP family, it is produced following exposure to cellular stressful situations such as excessive heat/cold, ultraviolet light and in the course of wound healing or tissue remodeling. HSP70 have chaperone functions through stabilizing proteins to certify correct folding or assisting in protein refolding (Rosenzweig et al., 2019). Moreover, HSP70 inhibits APAF1 binding with apoptosome and suppresses BAX binding to mitochondria, thus decreasing apoptosis rate in lung cancer cells (Wu et al., 2017). miR-206 binds with 3’UTR of SOX9, FMNL2, and KRAS. Down-regulation of miR-206 enhances protein levels of these genes in lung cancer (Shao et al., 2016).
TABLE 1 | Brief results of studies which gauged expression of RMRP in cancerous cell lines (↓: knock-down).

| Cancer types          | Targets/regulators and signaling pathways | Assessed cell lines                           | Function                                      | References               |
|-----------------------|------------------------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------|
| Bladder cancer        | miR-206                                  | BIU-87, T24, and SV-HUC-1                      | Δ RMRP: ↓ cell proliferation, migration, and invasion | Cao et al. (2019)        |
| Colorectal cancer     | Wnt and Hippo signaling pathways (p-catenin/YAP/TBX5) | SW480, HT-29, HCT116, HEK293, HEK293T, and Beas-2B | –                                             | Park and Jeong (2015)    |
| Hepatocellular carcinoma | miR-613                                | Hep3B, HCCLM3, and HL-7702                     | Δ RMRP: ↓ cell proliferation, migration, and invasion | Zhou et al. (2019)       |
|                       | miR-206/TACR1                            | SMMC-7721, Bel-7402, MHC-97, Hep2G2, Hep3B, Huh-7, and HL-7702 | Δ RMRP: ↓ cell proliferation, migration, invasion, and ↑ apoptosis | Hongfeng et al. (2020)   |
|                       | miR-766                                  | Hep3B, HepG2, MHC97H, Huh7, and HL-7702        | ↑ RMRP: ↓ cell proliferation, migration, invasion, and ↑ apoptosis | Shao et al. (2020)       |
| Cholangiocarcinoma    | miR-217                                  | HCCC-9810 and RBE                              | Δ RMRP: ↓ cell proliferation, migration, invasion and ↑ apoptosis | Tang et al. (2019)       |
| Gastric cancer        | miR-206/Cyclin D2                        | AGS, BGC-823, HGC-27, MGC-803, SGC-7901, and GES-1 | Δ RMRP: ↓ cell proliferation and ↑ apoptosis   | Shao et al. (2016)       |
| Gliona                | –                                       | U87 and U251                                   | Δ RMRP: ↓ cell proliferation, migration, invasion and ↑ apoptosis | Feng et al. (2017)       |
| Neuroblastoma         | miR-206/TACR1 and ERK1/2 pathway         | NB-1, SK-N-AS, and HEK293T                      | Δ RMRP: ↓ cell proliferation, migration, and invasion | Pan et al. (2019)        |
| Non-small cell lung cancer | miR-206/KRAS, FMNL2 and SOX9            | A549, SP-AL-1, H1299, H23, and 16HBE           | ↑ RMRP: ↑ cell proliferation, colony formation, and invasion | Shao et al. (2016)       |
|                       | miR-613/NFAT5                            | HCC827, 16HBE, H1299, H1975, A549, and HCT116  | Δ RMRP: ↓ cell proliferation, migration, and invasion | Yang et al. (2020)       |
|                       | miR-1-3p/ANXA2                           | A549, Calu1, H1299, H460, and BEAS-2B          | Δ RMRP: ↓ cells proliferation, migration and invasion | Tang et al. (2019)       |
| Papillary thyroid cancer | miR-675/MAPK1                            | HTH83, BCPAP, and TPC-1 and HT-ori3           | Δ RMRP: ↓ cell proliferation, migration and invasion | Wang et al. (2019)       |
| Multiple myeloma      | miR-34a-5p/Myc                           | NCI-H929, RPMI-8226 and NPCs                   | Δ RMRP: ↓ cell proliferation and ↑ apoptosis   | Kong et al. (2019)       |

Clinical Studies

Cao et al. (2019) have confirmed up-regulation of RMRP in bladder cancer samples in comparison with the nearby non-cancerous samples. Expression levels of RMRP have been correlated with tumor dimensions, lymph node metastasis and outcome of cancer in these patients (Cao et al., 2019). Levels of RMRP have also been up-regulated in clinical samples of colorectal and breast cancer patients (Park and Jeong, 2015). Over-expression of RMRP has also been reported in patients with hepatocellular carcinoma in correlation with tumor aggressiveness and adverse clinical outcome (Zhou et al., 2019). Accordingly, over-expression of RMRP has been identified as an indicator of poor prognosis in these patients (Hongfeng et al., 2020). In contrast with these studies, Shao et al. (2020) have reported down-regulation of RMRP in clinical xenograft model of gastric cancer, RMRP silencing attenuated tumor growth via modulation of miR-206 expression (Shao et al., 2016). A brief record of in vivo studies is shown in Table 2.

TABLE 2 | Brief reports of studies which assessed function of RMRP in cancer animal models (Δ: knock down or deletion).

| Cancer types          | Animal models                        | Function                                      | References               |
|-----------------------|--------------------------------------|-----------------------------------------------|--------------------------|
| Hepatocellular carcinoma | Male athymic Balb/c nude mice    | Δ RMRP: ↓ tumor size and weight               | Zhou et al. (2019)       |
|                       | Male Balb/c nude mice                | ↑ RMRP: ↓ tumor volume and weight             | Shao et al. (2020)       |
| Cholangiocarcinoma    | Male nude mice                       | Δ RMRP: ↓ tumor volume and weight             | Tang et al. (2019)       |
| Gastric cancer        | Male BALB/c nude mice                | Δ RMRP: ↓ tumor growth                        | Shao et al. (2016)       |
| Neuroblastoma         | Female athymic nude mice             | Δ RMRP: ↓ tumor volume and weight             | Pan et al. (2019)        |
| Non-small cell lung cancer | Male Balb/c nude mice             | Δ RMRP: ↓ tumor growth, migration and invasion | Yang et al. (2020)       |
| Multiple myeloma      | Male BALB/c-nude mice                | Δ RMRP: ↓ tumor growth                        | Kong et al. (2019)       |
samples obtained from patients with hepatocellular carcinoma. Under-expression of RMRP in these patients has been reported to be associated with low survival (Shao et al., 2020). RMRP expression has been increased in non-small cell lung cancer tissues in association with high clinical stage and poor patients' outcome (Tang et al., 2019). Expression of RMRP has been elevated in tissue, plasma and gastric juices obtained from patients with gastric cancer in association with Borrmann type and metastatic capacity. Notably, they reported suitability of levels of RMRP in plasma and gastric juice for diagnosis of gastric cancer (Shao et al., 2016). In the glioblastoma samples, RMRP over-expression has been associated with high tumor grade, low Karnofsky Performance Score and poor clinical outcome (Feng et al., 2017). A summary of experiments which appraised transcript levels of RMRP in clinical specimens from cancer patients is shown in Table 3.

Somatic mutations in the promoter region of this lncRNA have been firstly demonstrated in breast cancer

| Cancer types               | Samples                                                                 | Expression (tumor vs. normal) | Kaplan-Meier analysis                                                                 | References                  |
|---------------------------|-------------------------------------------------------------------------|-------------------------------|--------------------------------------------------------------------------------------|-----------------------------|
| Bladder cancer            | 91 paired of BC tissues and adjacent tissues                            | Up                            | Lower RMRP expression correlated with better prognosis.                               | Cao et al. (2019)           |
| Colorectal cancer (CRC)   | 8 paired of CRC tissues and ANTs                                        | Up                            | –                                                                                    | Park and Jeong (2015)       |
| Hepatocellular carcinoma (HCC) | 52 paired of HCC tissues and ANTs                                      | Up                            | Higher RMRP expression levels correlated with shorter OS in HCC patients compared with lower group. | Zhou et al. (2019)          |
|                           | 42 paired of HCC tissues and matched normal tissues                     | Up                            | RMRP high expression levels associated with decrease of OS rate in HCC patients.      | Hongfeng et al. (2020)      |
|                           | 40 paired of HCC tissues and ANTs                                      | Down                          | High RMRP expression levels correlated with better 5-years and median survival rates in HCC patients. | Shao et al. (2020)          |
| Cholangiocarcinoma (CCA)  | 33 paired of CCA tissues and ANTs                                       | Up                            | Patients with lower RMRP expression levels had longer OS.                            | Tang et al. (2019)          |
| Gastric cancer (GC)       | 132 paired of GC and non-tumorous tissues                              | Up                            | –                                                                                    | Shao et al. (2016)          |
| Gioma                     | 39 glioma tissues and 11 normal brain tissues                          | Up                            | Higher RMRP expression levels correlated with poorer OS in glioma patients than that of the lower group. | Feng et al. (2017)          |
| Neuroblastoma             | 44 paired of neonatal neuroblastoma tissues and ANTs                   | Up                            | Higher RMRP expression levels associated with poor prognosis in neonatal neuroblastoma patients. | Pan et al. (2019)           |
| Non-small cell lung cancer (NSCLC) | Plasma specimens from 63 NSCLC patients and 33 cancer-free smoker individuals | Up                            | –                                                                                    | Lin et al. (2018)           |
|                           | 35 paired of lung adenocarcinoma tissues and ANTs                      | Up                            | –                                                                                    | Shao et al. (2016)          |
|                           | 60 paired of NSCLC tissues and ANTs                                    | Up                            | RMRP high expression levels associated with decrease of OS rate in NSCLC patients.    | Yang et al. (2020)          |
|                           | 38 paired of NSCLC tissues and ANTs                                    | Up                            | Higher RMRP expression levels correlated with poorer OS in NSCLC patients compared to lower group. | Tang et al. (2019)          |
| Breast cancer (BC)        | 8 paired of BC tissues and ANTs                                        | Up                            | –                                                                                    | Park and Jeong (2015)       |
| Papillary thyroid cancer (PTC) | 57 paired of PTC tissues and ANTs                                      | Up                            | –                                                                                    | Wang et al. (2019)          |
| Multiple myeloma (MM)     | Bone marrow specimens from 28 MM patients and 10 healthy donors       | Up                            | High RMRP expression levels correlated with shorter disease-free survival and OS in MM patients. | Kong et al. (2019)          |
The hotspot mutation region in this study has been further assessed in another cohort of patients with diverse types of cancers showing the presence of RMRP promoter mutations in two gastric cancer samples, a colon carcinaoma sample and a sarcoma. Notably, none of these mutations has been formerly reported in breast cancers (Son et al., 2020). Table 4 shows the diverse mutations identified in the promoter region of RMRP in different solid and hematologic tumors.

Non-malignant Disorders

Han et al. (2020) have assessed the role of RMRP in lipopolysaccharide (LPS)-associated sepsis. They reported down-regulation of RMRP following LPS exposure. This down-regulation has been accompanied by significant reductions in MMP and mitochondrial cytochrome C levels, increased cardiomyocyte apoptosis, over-production of reactive oxygen species, up-regulation of cytochrome C in the cytoplasmic compartment, and over-production of caspase-3 and caspase-9 and NF-κB p65 subunit. Their in vivo experiments also verified the role of RMRP in the suppression of LPS-associated apoptosis and mitochondrial defects through sponging of miR-1-5p (Han et al., 2020). In fact, NF-κB family includes several transcription factors regulating expression of genes that partake in numerous crucial physiological responses including inflammatory reactions, cell proliferation, differentiation, cell adhesion and apoptosis (Karin et al., 2002). Thus, the regulatory role of RMRP on NF-κB p65 subunit potentiates this IncRNA as a contributor in many physiological and pathological processes.

An et al. (2020) have reported up-regulation of RMRP and Gadd45g in coronary atherosclerosis and human vascular smooth muscle cells, whereas miR-128-1-5P expression was decreased in these cells. RMRP silencing suppressed IL-6 and IL-8 production, and attenuated expression of apoptosis related proteins in these cells following ox-LDL treatment (An et al., 2020). Previous studies have indicated up-regulation of GADD45G in response to stressful growth arrest situations and exposure to DNA-damaging substances. In fact, GADD45G has an important role in response to environmental stress through facilitating activation of the p38/INK pathway (Takekawa and Saito, 1998). Moreover, GADD45G has been shown to be regulated by NF-κB (Tamura et al., 2012). Thus, the interaction between RMRP, GADD45G and NF-κB might be involved in a wide variety of human disorders.

Expression of RMRP has also been increased in the model of ischemic cerebral injury. Notably, valproate has an inhibitory effect on RMRP expression, while increasing PI3K/Akt activity leading to enhancement of cell viability and attenuation of apoptosis (Li and Sui, 2020). Up-regulation of RMRP has also been observed in a number of immune-related conditions. For instance, RMRP expression has been increased in T cells of patients with rheumatoid arthritis in correlation with disease duration (Moharamoghli et al., 2019). Finally, expression of RMRP has been significantly down-regulated in patients with major depressive disorder compared with normal individuals in correlation with severity of depression. Besides, RMRP levels were decreased in an animal model of depression (Seki et al., 2019). Table 5 reviews the role of RMRP in non-cancerous pathologic conditions.

| Type of cancers | Number of tumors | Wild type | Mutation | Location | Mutation (%) | References |
|----------------|-----------------|-----------|----------|----------|--------------|------------|
| Gastric carcinoma | 230 | 228 | 2 | Chr9:35,658,037|dupA | 0.9 | Son et al. (2020) |
| | | | | Chr9: 35,658,174|dupT | | |
| Colorectal carcinoma | 388 | 387 | 1 | Chr9:35,658,167G > T | 0.3 | Son et al. (2020) |
| Sarcoma | 70 | 69 | 1 (malignant fibrous histiocytoma) | Chr9,35,658,015_35,658,031, dupCACGTCCTCAGCTTCAC (17 bp) | 1.4 | Son et al. (2020) |
| Breast cancer | 360 | – | – | Chr9:35658033 G > A | – | Rheinbay et al. (2017) |
| Adulthood AML | 200 | 199 | 1 (AML with multilineage dysplasia) | g.35,658,020_35,658,039, dup CCTCAGCTCAGCAGATAGT (20 bp) | 0.5 | Son et al. (2019) |
| Adulthood ALL | 150 | 149 | 1 (B-ALL) | g.35,658,017_35,658,037, dup CGTCCTACGCTCAGCAGA (21 bp) | 0.7 | Son et al. (2019) |
| Childhood ALL | 200 | 199 | 1 (B-ALL) | g.35,658,029_35,658,041, dupCACAGATAGTTAT (13 bp) | 0.5 | Son et al. (2019) |
| Multiple myeloma | 75 | 74 | 1 | g.35,658,015_35,658,031, dup CACGTCCTCAGCAGC (17 bp) | 0 | Son et al. (2019) |
TABLE 5 | Summary of RMRP studies in non-cancerous pathologic conditions.

| Pathologic conditions                                      | Clinical samples                                                                 | Cell lines                          | Animal models                   | Targets/regulators and signaling pathways | Results                                                                 | References          |
|------------------------------------------------------------|----------------------------------------------------------------------------------|------------------------------------|---------------------------------|------------------------------------------|--------------------------------------------------------------------------|---------------------|
| Sepsis (myocardial dysfunction)                            | –                                                                                | Murine HL-1 cardiomyocytes         | Male C57B6/L mice               | miR-1-5p/HSPA4                           | RMRP regulated cardiomyocyte apoptosis and inhibited Lipopolysaccharide-induced sepsis. | Han et al. (2020)    |
| Atherosclerosis                                            | –                                                                                | Human vascular smooth muscle cells, HEK293T | Wistar rats                     | miR-128-1-5P/Gadd45g                    | RMRP was upregulated in coronary atherosclerosis. Its downregulation associated with inhibition of IL-6, IL-8, and apoptosis related proteins. | An et al. (2020)    |
| Ischemic heart failure (HF)                                | PBMC and left ventricle biopsies of 18 non-end-stage dilated ischemic cardiomyopathy and 17 controls/11 post-ischemic end-stage HF patients | –                                  | CS7BL/6 J male mice              | –                                        | RMRP was dysregulated in both end- and non-end-stage HF patients and mouse model of cardiac hypertrophy. | Greco et al. (2016) |
| Ischemic myocardial injury                                 | –                                                                                | H8c2                               | Sprague-Dawley male rats        | miR-206/ATG3 and PI3K/akt/mTOR pathway   | RMRP downregulation enhanced cardiac function and suppressed apoptosis followed by myocardial I/R injury. | Kong et al. (2019)  |
| Cardiac fibrosis                                            | –                                                                                | –                                  | pathogen-free Sprague-Dawley rats | miR-613                                  | RMRP was upregulated in cardiac fibrosis. Its reduction led to inhibition of cardiac proliferation, differentiation and collagen accumulation. | Zhang et al. (2019) |
| Ischemic stroke (IS)                                       | –                                                                                | BV-2                               | Adult male CS7BL/6 mice          | PI3K/Akt signaling pathway               | Valproate inhibited RMRP expression, which increased survival rates and modulated cell apoptosis. | Li and Sui (2020)   |
| Multiple sclerosis (MS)                                    | Whole venous blood from 72 patients and 28 healthy controls                     | –                                  | –                               | Th17 effector program                    | RMRP gene expression tended to be increased in patients with relapsing-remitting form of MS. | Ghaiaid et al. (2020) |
| Rheumatoid arthritis (RA)                                  | Peripheral blood from 20 RA patients and 18 healthy matched controls            | –                                  | –                               | –                                        | RMRP expression was upregulated in T cells of RA patients and correlated with disease duration. | Moharamoghi et al. (2019) |
| Major depressive disorder (MDD)                            | Peripheral blood from 29 MDD patients and 29 matched healthy controls           | –                                  | Adult male BALB/c mice           | –                                        | RMRP was downregulated in MDD patients and mouse model. It was correlated with depression severity. | Seki et al. (2019)  |

DISCUSSION

Over-expression of RMRP has been reported in numerous types of cancers such as those originated from bladder, colorectal, lung, breast and gastric tissues. Moreover, up-regulation of RMRP is a marker of poor prognosis in these types of cancers. The results of in vitro and in vivo studies consistently verify this function for RMRP with a single exception in the hepatocellular carcinoma. In spite of vast mechanistical studies about the role of RMRP, the net situation of RMRP as a diagnostic marker in cancer has not been evaluated yet.

RMRP serves as a sponge for miR-206, miR-613, miR-1-3p, and miR-217. Among these miRNAs, the functional interaction between RMRP and miR-206 has been approved in different tissues. In addition to these miRNAs, expressions of tens of miRNAs have been altered following RMRP silencing,
implying the vast extent of RMRP/miRNA network (Tang et al., 2019). Functional annotation of dysregulated miRNAs depicted their relevance with structural molecular functions, extracellular matrix elements, retinoid/isoprenoid binding, functions of cytokines and IFN-α/β receptor binding (Tang et al., 2019). Almost all of these functions are related to the carcinogenesis process. Therefore, a possible route for participation of RMRP in this process is its interactions with miRNAs. One of the pathways being influenced RMRP is stem cells metabolism (Tang et al., 2019) which accords with the formerly reported role of RMRP in giving permission to cancer cells for infinite proliferation via interplay with TERT (Maida et al., 2009).

In addition to the mentioned malignant conditions, dysregulation of RMRP has been reported in ischemic myocardial injury, cardiac fibrosis, ischemic stroke, multiple sclerosis, rheumatoid arthritis and major depressive disorder. Evidence for contribution of RMRP in the pathogenesis of major depressive disorder has come from both human and rodent studies (Seki et al., 2019). Moreover decreased levels of this IncRNA in the circulation of patients potentiate it as a biomarker for this neuropsychiatric condition (Seki et al., 2019). The role of RMRP in construction of the nuclear RNase MRP complex and its function in the processing of ribosomal RNA, its effects in the regulation of epigenetic mechanisms and its interactions with the telomerase reverse transcriptase catalytic subunit have been suggested as possible mechanisms of participation of RMRP in major depressive disorder (Seki et al., 2019). Therefore, RMRP is involved in the development of diverse disorders. This finding is in accordance with the ubiquitous expression of RMRP in human tissues. Functionally, the majority of effects of RMRP in the pathogenesis of these disorders are explained by the regulatory role of this IncRNA in the mitochondrial functions particularly apoptotic pathways regulated by this organelle. In addition, based on the interaction between RMRT and miRNAs regulating cytokine activity, modulation of immune function is another mechanism of participation of RMRT in the development of these disorders especially rheumatoid arthritis and multiple sclerosis.

A major limitation of most of studies that assessed expression of RMRP in cancer patients is the small sample size and lack of validation of the obtained results in independent cohorts. Moreover, they have not assessed expression of this IncRNA in the circulation to unravel its potential as non-invasive biomarker. Taken together, RMRP is an IncRNA whose dysregulation and somatic mutations have been demonstrated in solid and hematological malignancies. However, the association between the observed mutations and altered expression of this IncRNA has not been assessed yet. Thus, this field should be explored in future studies.

**FUTURE DIRECTIONS**

Recent advances in high throughput sequencing techniques have facilitated identification of molecular counterparts of IncRNAs. Further attempts in this field would identify additional mRNA and miRNA molecules that function in upstream and downstream of RMRP, thus extending the functional network through which this IncRNA exerts its effects. Comprehensive assessment of these network would help in recognition of the most appropriate therapeutic targets for treatment of RMRT-associated disorders.

**AUTHOR CONTRIBUTIONS**

MT and SG-F wrote the draft and revised it. BH, TA, and HH collected the data and designed the tables and figures. All authors approved submitted version.

**REFERENCES**

An, I., Chen, Z., Ma, Q., Li, Y., and Shi, F. (2020). Liraglutide improves atherosclerosis by regulating long non-coding RNA RMRP/miR-128-1-5p/Gadd45g axis. *Eur. Rev. Med. Pharmacol. Sci.* 24, 2725–2737.

Binney, E., Stamatoyannopoulos, J., Dutta, A., Guigó, R., Gingeras, T., Margulies, E., et al. (2007). Baylor college of medicine human genome sequencing center; Washington university genome sequencing center; Broad institute; Children’s hospital oakland research institute. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature* 447, 799–816.

Boya, P., and Kroemer, G. (2008). Lysosomal membrane permeabilization in cell death. *Oncogene* 27, 6434–6451. doi: 10.1038/onc.2008.310

Cao, H., Liu, Z., Huang, P., Yue, Y., and Xi, J. (2019). lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. *Eur. Rev. Med. Pharmacol. Sci.* 23, 1012–1021.

Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M., Maeda, N., et al. (2005). The transcriptional landscape of the mammalian genome. *Science* 309, 1559–1563. doi: 10.1126/science.1112014

Chang, D. D., and Clayton, D. A. (1987). A mammalian mitochondrial RNA processing activity contains nucleus-encoded RNA. *Science* 235, 1178–1184. doi: 10.1126/science.2434997

Consortium, E. P. (2012). An integrated encyclopedia of DNA elements in the human genome. *Nature* 489:57. doi: 10.1038/nature11247

Dahariya, S., Paddibhatla, I., Kumar, S., Raghuvanshi, S., Pallelpati, A., and Guttii, R. K. (2019). Long non-coding RNA: classification, biogenesis and functions in blood cells. *Mol. Immunol.* 112, 82–92. doi: 10.1016/j.molimm.2019.04.011

Feng, W., Li, L., Xu, X., Jiao, Y., and Du, W. (2017). Up-regulation of the long non-coding RNA RMRP contributes to glioma progression and promotes glioma cell proliferation and invasion. *Arch. Med. Sci.* 13:1315. doi: 10.5114/ams.2017.66747

Ghaiad, H. R., Elmazny, A. N., Nooh, M. M., El-Sawalhi, M. M., and Shaheen, A. A. (2020). Long noncoding RNAs APOA1-AS, IFNG-AS1, RMRP and their related biomolecules in Egyptian patients with relapsing-remitting multiple sclerosis: Relation to disease activity and patient disability. *J. Adv. Res.* 21, 141–150. doi: 10.1016/j.jare.2019.10.012

Greco, S., Zaccagnini, G., Perfetti, A., Fuschi, P., Valaperta, R., Voellenkle, C., et al. (2016). Long noncoding RNA dysregulation in ischemic heart failure. *J. Transl. Med.* 14:183.

Guo, K., and Jin, F. (2015). NFAT5 promotes proliferation and migration of lung adenocarcinoma cells in part through regulating AQ5P expression. *Biochem. Biophys. Res. Commun.* 465, 644–649. doi: 10.1016/j.bbrc.2015.08.078

Han, Y., Cai, Y., Lai, X., Wang, Z., Wei, S., Tan, K., et al. (2020). lncRNA RMRP promotes mitochondrial dysfunction and cardiomyocyte apoptosis via the miR-1-5p/hsp70 Axis in LPS-induced sepsis mice. *Inflammation* 43, 605–618. doi: 10.1007/s10753-019-01141-8

Hauck, F., Voss, R., Urban, C., and Seidel, M. G. (2018). Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. *J. Allergy Clin. Immunol.* 141, 59–68. doi: 10.1016/j.jaci.2017.06.009
Hussn et al.

RMRP and Human Disorders

Hermanns, P., Bertuch, A. A., Bertin, T. K., Dawson, B., Schmitt, M. E., Shaw, C., et al. (2005). Consequences of mutations in the non-coding RMRP RNA in cartilage-hair hypoplasia. Hum. Mol. Genet. 14, 3723–3740. doi: 10.1093/hmg/ddi403

Hongfeng, Z., Andong, J., Liwen, S., Mingping, B., Xiaowei, Y., Mingyong, L., et al. (2020). IncRNA RMRP knockdown suppress hepatocellular carcinoma biological activities via regulation miR-206/TACR1. J. Cell. Biochem. 121, 1690–1702. doi: 10.1002/jcb.29404

Huang, B., Zhai, W., Hu, G., Huang, C., Xie, T., Zhang, J., et al. (2016). MicroRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer. Oncotarget 7:37812.

Son, H. J., Choi, E. J., Yoo, N. J., and Lee, S. H. (2019). Somatic mutations in long non-coding RNA RMRP in acute leukemias. Pathol. Res. Practice. 215:15264. doi: 10.1016/j.prp.2019.152647

Son, H. J., Mo, H. Y., Choi, E. J., Yoo, N. J., and Lee, S. H. (2020). Promoter mutation analysis of long non-coding RNA RMRP gene in solid tumors. Pathol. Oncol. Res. 26, 2809–2810. doi: 10.1007/s11253-019-00723-z

Stark, B. C., Kole, R., Bowman, E. J., and Altman, S. (1978). Ribonuclease P: an enzyme with an essential RNA component. Proc. Natl. Acad. Sci. U. S. A. 75, 3717–3721.

Sun, S.-C. (2011). Non-canonical NF-κB signaling pathway. Cell Res. 21, 71–85. doi: 10.1038/cr.2010.177

Sun, Z., Zhang, R., Liu, M., Chen, H., Chen, L., Luo, F., et al. (2019). RMRP mutation disrupts chondrogenesis and bone ossification in zebrafish model of cartilage-hair hypoplasia via enhanced Wnt/β-catenin signaling. Bone Res. 7:13. doi: 10.1038/s41413-019-0101-5

Takekawa, M., and Saito, H. (1998). A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MKT1/MRK4 MAPKKK. Cell 95, 521–530. doi: 10.1016/s0092-8674(00)8169-0

Temple, M. R., and Donaldson, D. (1999). Consequences of mutations in the non-coding RMRP RNA in cartilage-hair hypoplasia. J. Med. Genet. 36, 112–116. doi: 10.1136/jmg.36.2.112

Tong, L., Wang, Y., Wang, H., Xu, B., Ji, H., Xu, G., et al. (2019). Long noncoding-RNA component of mitochondrial RNA processing endonuclease is involved in the progression of cholangiocarcinoma by regulating miRNA-217. Cancer Sci. 110:103. doi: 10.1111/cjs.14074

Tasaki, N., Kesakian, L., Kajihara-Lindberg, M.-L., Mäkitie, A., Mäkitie, O., and Ranki, A. (2013). Combining cancer predisposition in association with idiopathic immune deficiency: a recurrent nodal and cutaneous T-cell lymphoproliferative disease in a patient with cartilage-hair hypoplasia. Clin. Lymphoma Myeloma Leukemia. 2018:148. doi: 10.1016/j.clml.2018.07.005

Vakkilainen, S., Taskinen, M., Pukkala, E., and Mäkitie, O., et al. (2019a). The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2. Sci. Rep. 9, 1–9.

Vakkilainen, S.,Taskinen, M., Klemetti, P., Pukkala, E., and Mäkitie, O., et al. (2019b). The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2. Sci. Rep. 9, 1–9.

Yang, M., Ke, H., and Zhou, W. (2020). LncRNA RMRP promotes cell proliferation and invasion through miR-613/NFAT5 axis in non-small cell lung cancer. J. Transl. Med. 18:470. doi: 10.1186/s12967-020-02242-z

Zhou, N., He, Z., Tang, H., Jiang, B., and Cheng, W. (2019). LncRNA RMRP/miR-613 axis is associated with poor prognostics and enhances the tumorigenesis of hepatocellular carcinoma by impacting oncogenic phenotypes. J. Transl. Med. 17:2801.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hussn, Azimi, Hidayat, Taheri and Ghafoori-Fard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.